Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease

International Journal of Molecular Sciences, Journal Year: 2022, Volume and Issue: 23(13), P. 7280 - 7280

Published: June 30, 2022

Nonalcoholic fatty liver disease (NAFLD) is a global pandemic that affects one-quarter of the world’s population. NAFLD includes spectrum progressive from steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis can be complicated by hepatocellular carcinoma. It strongly associated with metabolic syndromes, obesity, type 2 diabetes, it has been shown dysregulation central its pathogenesis. Recently, suggested metabolic- (dysfunction) (MAFLD) more appropriate term describe than NAFLD, which puts increased emphasis on important role dysfunction in There strong evidence mitochondrial plays significant development progression NAFLD. Impaired acid oxidation and, recently, reduction quality, have play major progression. In this review, we provide an overview our current understanding highlight how contributes pathogenesis both animal models human subjects. Further discuss modification function modulates targeting mitochondria promising new avenue for drug treat NAFLD/NASH.

Language: Английский

---

The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2023, Volume and Issue: 20(12), P. 764 - 783

Published: Aug. 15, 2023

Language: Английский

---

Relationship between NAFLD and coronary artery disease: A Mendelian randomization study

Hepatology, Journal Year: 2022, Volume and Issue: 77(1), P. 230 - 238

Published: April 20, 2022

Background and Aims: There is an ongoing debate on whether NAFLD active contributor or innocent bystander in the pathogenesis of coronary artery disease (CAD). The aim present study was to assess causal relationship between CAD. Approach Results: We performed two‐sample Mendelian randomization (MR) analyses using summary‐level data association genetically predicted (i.e., chronically elevated serum alanine aminotransferase levels [cALT], imaging‐based biopsy‐confirmed NAFLD) risk Analyses were repeated after exclusion susceptibility genes that are associated with impaired VLDL secretion. Inverse‐variance weighted MR showed a statistically significant cALT CAD (OR: 1.116, 95% CI: 1.039, 1.199), but not for other NAFLD‐related traits 1.046, 0.764, 1.433 OR: 1.014, 0.968, 1.062 NAFLD, respectively). MR‐Egger regression revealed intercept, indicative directional pleiotropy, all traits. Repeat secretion consistent associations [OR: 1.203, 1.113, 1.300]), 2.149, 1.276, 3.620) 1.041, 1.189), which persisted when more stringent criteria used 1.154, 1.043, 1.278) methods applied. did show intercept. Conclusion: robust genetic variants implicated

Language: Английский

---

Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties

Journal of Hepatology, Journal Year: 2023, Volume and Issue: 79(1), P. 209 - 217

Published: Feb. 4, 2023

Language: Английский

---

Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease

Journal of the American College of Cardiology, Journal Year: 2022, Volume and Issue: 79(2), P. 180 - 191

Published: Jan. 1, 2022

Language: Английский

---